Cullinan Therapeutics (NASDAQ:CGEM) expects 2026 to be a catalyst-heavy year across its pipeline, led by two “high-priority” T-cell engager programs in autoimmune disease and acute myeloid leukemia (AML), according to comments from CEO Nadim Ahmed and Chief Medical Officer Jeffrey Jones during a Guggenheim fireside chat. Ahmed said the company laid out milestones “starting from […]